Nanohale AG (ETR:FYB) | Finanzwire

Basculer en Français

10603	Companies
225009	Keywords
153732	Articles
119071	Press releases

Home
Companies
Nanohale AG

BRIEF

published on 02/24/2025 at 11:31, 1 year 3 months ago

Formycon AG: Price Target Adjusted Amid Market Pressures

Buy Recommendation Formycon AG Price Pressure Biosimilar Market Investment Reduction
PRESS RELEASE

published on 02/24/2025 at 11:26, 1 year 3 months ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates its research on Formycon AG, maintaining a Buy recommendation with a decreased target price from EUR 82 to EUR 46 due to higher price pressure and reduced investments in biosimilar portfolio

First Berlin Equity Research Buy Recommendation Research Update Formycon AG Biosimilar Portfolio
BRIEF

published on 02/20/2025 at 06:35, 1 year 4 months ago

Formycon Unveils Clinical Data for Ustekinumab Biosimilar FYB202 at ECCO Congress

Formycon AG Regulatory Approval Clinical Data Biosimilar FYB202
PRESS RELEASE

published on 02/20/2025 at 06:30, 1 year 4 months ago

Formycon presents clinical data on ustekinumab biosimilar FYB202 at the ECCO Congress in Berlin
Formycon presents clinical data on ustekinumab biosimilar FYB202 at ECCO Congress, demonstrating comparability with Stelara. FYB202 approved in multiple regions

Clinical Data ECCO Congress Biosimilar Formycon Ustekinumab
BRIEF

published on 02/17/2025 at 09:32, 1 year 4 months ago

Formycon AG Updates on Biosimilar Projects and Strategic Adjustments

FDA Approval Biosimilars Financial Adjustments Commercial Strategy Price Discounts
PRESS RELEASE

published on 02/17/2025 at 09:27, 1 year 4 months ago

Formycon AG informs about recent developments in various biosimilar projects and invites to conference call
Formycon AG provides updates on various biosimilar projects, including terminating phase III trial for FYB206. Conference call on Feb 17, 2025, to discuss recent developments

FDA Conference Call Formycon AG FYB206 Biosimilar Projects
BRIEF

published on 02/17/2025 at 08:10, 1 year 4 months ago

Formycon Updates on Phase III Trial and Valuation Adjustments

Formycon AG FDA Feedback Phase III Trial Commercialization Strategy Biosimilar Valuation
PRESS RELEASE

published on 02/17/2025 at 08:05, 1 year 4 months ago

EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts

FDA Feedback Valuation Adjustments Formycon FYB206 Price Discounts
BRIEF

published on 02/05/2025 at 06:35, 1 year 4 months ago

Lotus Pharmaceutical Partners with Formycon to Commercialize Eylea® Biosimilar in Asia-Pacific

Lotus Pharmaceutical Eylea® Biosimilar Asia-Pacific Commercialization FDA And EU Approval Retinal Disease Treatment
PRESS RELEASE

published on 02/05/2025 at 06:30, 1 year 4 months ago

Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Formycon AG announces strategic partnership with Lotus Pharmaceutical for commercialization of Eylea biosimilar FYB203/AHZANTIVE in Asia-Pacific region

Formycon AG Asia-Pacific Eylea Biosimilar FYB203/AHZANTIVE Lotus Pharmaceutical

Accesswire

Published on 06/20/2026 at 01:00, 14 hours 36 minutes ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 15 hours 36 minutes ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 1 day 11 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 1 day 14 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting
Published on 06/19/2026 at 01:07, 1 day 14 hours ago

Usha Resources Announces Share Issuance in Payment of Debenture Interest, Adopts Semi-Annual Reporting

View all ACCESSWIRE

EQS Group

Published on 06/20/2026 at 06:00, 9 hours 36 minutes ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 19 hours 19 minutes ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations
Published on 06/19/2026 at 19:01, 20 hours 35 minutes ago

Fuller, Smith & Turner PLC: Publication of the Annual Report and Accounts for the 52 weeks ending 28 March 2026 and Notice of 2026 Annual General Meeting
Published on 06/19/2026 at 18:29, 21 hours 7 minutes ago

Designated Person Notification
Published on 06/19/2026 at 18:00, 21 hours 36 minutes ago

Successful issue of a CHF 100 million green bond

Les Echos

Published on 06/19/2026 at 19:33, 20 hours 3 minutes ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 20 hours 12 minutes ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/18/2026 at 18:00, 1 day 21 hours ago

Outstanding shares and voting rights statement at 31 May 2026
Published on 06/18/2026 at 17:45, 1 day 21 hours ago

EURAZEO INVESTS IN LAURALU, A PAN-EUROPEAN PROVIDER OF DEPLOYABLE INDUSTRIAL INFRASTRUCTURE
Published on 06/18/2026 at 17:38, 1 day 21 hours ago

Statement of transactions in own shares from June 8, 2026 to June 12, 2026

View all LES ECHOS COMFI WIRE